Company intelligence / Profile preview

CardioPharma

Wilmington, North Carolina, United Statescardio-pharma.com ↗

Ownership: Private
Development stage: Other

Overview

CardioPharma is developing fixed-dose combination oral therapies for cardiovascular disease. Its lead product, CardiaPill®, combines a statin, an ACE inhibitor, and an anti-platelet agent to improve patient adherence and outcomes. The company has secured global patents for its formulations but has not yet reported late-stage clinical results or commercial launches[2][6].

Therapeutic areas: Cardiovascular
Modalities: Small moleculeCombination therapy (fixed-dose combination)
Industry: Biotech

Drug pipeline

4 assets

CardiaPill

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Patents licensed from Harvard’s Brigham and Women’s Hospital and Massachusetts College of Pharmacy[2]. No major pharma partnerships disclosed.

Beyond the preview

Go deeper on CardioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioPharma.

Explore the full profile